{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:30:02Z","timestamp":1793478602223,"version":"4.5.0"},"reference-count":214,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.prp.2026.156711","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T09:08:21Z","timestamp":1792228101000},"page":"156711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Biomarker-guided targeted therapy in lung adenocarcinoma: A concise review of precision oncology advances, resistance mechanisms, and emerging strategies"],"prefix":"10.1016","volume":"288","author":[{"given":"Tanisqa","family":"Mall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishwajeet","family":"Bachhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibha","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8333-1494","authenticated-orcid":false,"given":"Meng-Chih","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6515-3268","authenticated-orcid":false,"given":"Chien-Hsing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2021-5327","authenticated-orcid":false,"given":"Chung-Hsien","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiung-I","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Ping","family":"Chang-Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakthivel","family":"Kogularasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2026.156711_bib1","series-title":"StatPearls [Internet]","article-title":"Lung adenocarcinoma","author":"Myers","year":"2023"},{"key":"10.1016\/j.prp.2026.156711_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4155\/fmc-2023-0331","article-title":"Mucin Glycosylation: A Potential Target for Prostate Cancer Management","volume":"16","author":"Mall","year":"2024","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.prp.2026.156711_bib3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s40203-025-00422-5","article-title":"Molecular docking, molecular dynamics simulation, and ADME profiling of novel benzoxazolone-based OGT inhibitors","volume":"13","author":"Mall","year":"2025","journal-title":"Silico Pharmacol."},{"key":"10.1016\/j.prp.2026.156711_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1753465815617871","article-title":"Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches","volume":"10","author":"Shea","year":"2016","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.prp.2026.156711_bib5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nrclinonc.2015.90","article-title":"Refining the treatment of NSCLC according to histological and molecular subtypes","volume":"12","author":"Thomas","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrc.2016.56","article-title":"Biomarker development in the precision medicine era: lung cancer as a case study","volume":"16","author":"Vargas","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2026.156711_bib7","article-title":"Therapy for Stage IV Non\u2013Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2","volume":"44","author":"Puri","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib8","article-title":"Therapy for Stage IV Non\u2013Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0","volume":"44","author":"Puri","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib9","doi-asserted-by":"crossref","first-page":"S994","DOI":"10.1016\/j.annonc.2022.07.1103","article-title":"975P Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial","volume":"33","author":"Smit","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41698-025-01144-9","article-title":"MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer","volume":"9","author":"Tsao","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2020.11.023","article-title":"Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer","volume":"151","author":"Elfving","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.prp.2026.156711_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13000-023-01426-5","article-title":"Validation and interpretation of Pan-TRK immunohistochemistry: a practical approach and challenges with interpretation","volume":"19","author":"Karakas","year":"2024","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.prp.2026.156711_bib13","unstructured":"U.S. U.S Food and Drug Administration, Premarket Approval (PMA): PD-L1 IHC 22C3 pharmDx, (2015). https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P150013 (accessed September 10, 2026)."},{"key":"10.1016\/j.prp.2026.156711_bib14","unstructured":"U.S. U.S Food and Drug Administration, Guardant360 CDx \u2013 Premarket Approval (PMA) P200010, (2026). FDA Guardant360 CDx PMA P200010 (accessed September 10, 2026)."},{"key":"10.1016\/j.prp.2026.156711_bib15","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jtho.2018.05.030","article-title":"Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC","volume":"13","author":"Rolfo","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib16","doi-asserted-by":"crossref","first-page":"vii56","DOI":"10.1093\/annonc\/mds226","article-title":"Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Peters","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib17","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.3390\/curroncol29070396","article-title":"Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer","volume":"29","author":"Ionescu","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib18","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.prp.2026.156711_bib20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jtho.2017.12.001","article-title":"Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors","volume":"13","author":"Lindeman","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202300245","article-title":"Synthesis and biological profile of benzoxazolone derivatives","author":"Prasher","year":"2023","journal-title":"Arch. Pharm. (Weinh."},{"key":"10.1016\/j.prp.2026.156711_bib22","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.3390\/ijms25115917","article-title":"Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer","volume":"25","author":"Seo","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156711_bib23","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156711_bib24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib25","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2026.156711_bib26","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2026.156711_bib27","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1158\/2159-8290.CD-18-1022","article-title":"Landscape of Acquired Resistance to Osimertinib in EGFR -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion","volume":"8","author":"Piotrowska","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prp.2026.156711_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00126","article-title":"Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR -Mutant Lung Cancers","author":"Offin","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib29","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2026.156711_bib30","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221144099","article-title":"Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer","volume":"14","author":"Lee","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12964-023-01082-8","article-title":"Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer","volume":"21","author":"Li","year":"2023","journal-title":"Cell. Commun. Signal."},{"key":"10.1016\/j.prp.2026.156711_bib32","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.21037\/tlcr-24-193","article-title":"Overcoming acquired resistance following osimertinib administration in EGFR-mutant lung adenocarcinoma","volume":"13","author":"Kaira","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.prp.2026.156711_bib33","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.18.02236","article-title":"ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non\u2013Small-Cell Lung Cancer","volume":"37","author":"Shaw","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib34","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","article-title":"Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer","volume":"8","author":"Yoda","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prp.2026.156711_bib35","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK -Rearranged Lung Cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prp.2026.156711_bib36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41698-023-00350-7","article-title":"Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer","volume":"7","author":"Katayama","year":"2023","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib37","article-title":"Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies","volume":"7","author":"Sanchez-Cespedes","year":"2026","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.prp.2026.156711_bib38","doi-asserted-by":"crossref","first-page":"15056","DOI":"10.3390\/ijms232315056","article-title":"Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance","volume":"23","author":"Wu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156711_bib39","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1158\/1535-7163.MCT-21-0221","article-title":"TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations","volume":"20","author":"Murray","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.prp.2026.156711_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.9076","article-title":"SAF-189s in advanced, ALK-positive, non\u2013small cell lung cancer: Results from a first-in-human phase 1\/2, multicenter study","volume":"40","author":"Yang","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1328728","article-title":"Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer","volume":"14","author":"Chour","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib42","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.21037\/tlcr-2025-164","article-title":"Literature review of advances and challenges in KRAS G12C mutant non-small cell lung cancer","volume":"14","author":"Yuan","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.prp.2026.156711_bib43","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","article-title":"FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156711_bib44","doi-asserted-by":"crossref","first-page":"6455","DOI":"10.3390\/ijms27146455","article-title":"KRAS G12C\u2013Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone","volume":"27","author":"Rosas","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156711_bib45","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.3390\/cancers17172803","article-title":"KRAS G12C Inhibition in Solid Tumors: Biological Breakthroughs, Clinical Evidence, and Open Challenges","volume":"17","author":"Vitiello","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prp.2026.156711_bib46","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","article-title":"The current state of the art and future trends in RAS-targeted cancer therapies","volume":"19","author":"Punekar","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib47","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired Resistance to KRAS G12C Inhibition in Cancer","volume":"384","author":"Awad","year":"2021","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156711_bib48","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 Fusion\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156711_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70017","article-title":"Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer","volume":"14","author":"Desilets","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.prp.2026.156711_bib50","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00044-026-03606-6","article-title":"Zidesamtinib (Jideytro\u00ae): a new selective, brain-penetrant ROS1 inhibitor approved for the treatment of ROS1-positive non-small cell lung cancer","volume":"35","author":"Lee","year":"2026","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.prp.2026.156711_bib51","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1158\/1078-0432.CCR-15-2013","article-title":"A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1 -Rearranged Lung Cancer","volume":"22","author":"Drilon","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156711_bib52","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41571-020-0408-9","article-title":"ROS1-dependent cancers \u2014 biology, diagnostics and therapeutics","volume":"18","author":"Drilon","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib53","doi-asserted-by":"crossref","unstructured":"R. Thawani, M. Repetto, C. Keddy, K. Nicholson, K. Jones, K. Nusser, C.Z. Beach, G. Harada, A. Drilon, M.A. Davare, TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers, (2024). https:\/\/doi.org\/10.1101\/2024.01.16.575901.","DOI":"10.1101\/2024.01.16.575901"},{"key":"10.1016\/j.prp.2026.156711_bib54","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1158\/1078-0432.CCR-21-0032","article-title":"Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion\u2013Positive Lung Cancer","volume":"27","author":"Lin","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156711_bib55","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00894-017-3314-z","article-title":"Gaining insight into crizotinib resistance mechanisms caused by L2026M and G2032R mutations in ROS1 via molecular dynamics simulations and free-energy calculations","volume":"23","author":"Wu","year":"2017","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.prp.2026.156711_bib56","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3390\/curroncol32110626","article-title":"Evolving Therapeutic Landscape of ROS1-Positive Non-Small Cell Lung Cancer: An Updated Review","volume":"32","author":"Bischoff","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib57","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET Exon 14\u2013Mutated or MET -Amplified Non\u2013Small-Cell Lung Cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156711_bib58","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in Non\u2013Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations","volume":"383","author":"Paik","year":"2020","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156711_bib59","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/1078-0432.CCR-21-1566","article-title":"FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations","volume":"28","author":"Mathieu","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156711_bib60","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s40265-025-02210-z","article-title":"Telisotuzumab Vedotin: First Approval","volume":"85","author":"Blair","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.prp.2026.156711_bib61","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/oncolo\/oyac264","article-title":"RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape","volume":"28","author":"Novello","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.prp.2026.156711_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1033484","article-title":"Targeted therapy of RET fusion-positive non-small cell lung cancer","volume":"12","author":"Shen","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1264231","article-title":"Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report","volume":"13","author":"Leite","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib64","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0224","article-title":"Mechanisms of resistance to RET-directed therapies","volume":"32","author":"Clifton-Bligh","year":"2025","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.prp.2026.156711_bib65","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib66","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1078-0432.CCR-20-2278","article-title":"Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion\u2013Positive Lung Cancer by Combining Selpercatinib with Crizotinib","volume":"27","author":"Rosen","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156711_bib67","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1158\/1535-7163.MCT-21-0127","article-title":"The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation","volume":"20","author":"Jiang","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.prp.2026.156711_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105543","article-title":"BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation\/expansion multicenter study","volume":"10","author":"Sch\u00f6ffski","year":"2025","journal-title":"ESMO Open."},{"key":"10.1016\/j.prp.2026.156711_bib69","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jtho.2021.08.011","article-title":"Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis","volume":"17","author":"Planchard","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib70","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2217\/fon-2021-1250","article-title":"Encorafenib Plus Binimetinib in Patients with BRAF V600 -Mutant Non-Small Cell Lung Cancer: Phase II PHAROS Study Design","volume":"18","author":"Riely","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib71","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.lungcan.2022.05.014","article-title":"Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions","volume":"169","author":"Riudavets","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.prp.2026.156711_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2025.12.001","article-title":"Biology and Clinical Management of Non-V600 BRAF Alterations in NSCLC","volume":"21","author":"Ortiz-Cuaran","year":"2026","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib73","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/ijms25010624","article-title":"Molecular Targeting of the BRAF Proto-Oncogene\/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers","volume":"25","author":"Shan","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156711_bib74","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12094-022-02849-0","article-title":"BRAF\/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it","volume":"25","author":"Tsamis","year":"2022","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib75","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2 -Mutant Non\u2013Small-Cell Lung Cancer","volume":"386","author":"Li","year":"2022","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156711_bib76","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab Deruxtecan in Patients With HER2 -Mutant Metastatic Non\u2013Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial","volume":"41","author":"Goto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib77","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1158\/2159-8290.CD-25-0647","article-title":"Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding","volume":"16","author":"Chen","year":"2026","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prp.2026.156711_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2026.01.007","article-title":"Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs","author":"Nilsson","year":"2026","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib79","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3390\/biom15101443","article-title":"Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer","volume":"15","author":"Ekyalongo","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.prp.2026.156711_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2026.109514","article-title":"Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer","volume":"218","author":"Radonic","year":"2026","journal-title":"Lung Cancer"},{"key":"10.1016\/j.prp.2026.156711_bib81","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41379-018-0118-3","article-title":"Molecular characterization of cancers with NTRK gene fusions","volume":"32","author":"Gatalica","year":"2019","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2026.156711_bib82","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib83","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/neuonc\/noab274","article-title":"Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors","volume":"24","author":"Doz","year":"2022","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib84","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib85","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.prp.2026.156711_bib86","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156711_bib87","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prp.2026.156711_bib88","article-title":"Primary and acquired resistance to immunotherapy in NSCLC","volume":"17","author":"Yuan","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156711_bib89","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41698-026-01474-2","article-title":"Multi-omics profiling reveals tumor microenvironment characteristics linked to immunotherapy response and prognosis in non-small cell lung cancer","volume":"10","author":"Zhang","year":"2026","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib90","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non\u2013Small-Cell Lung Cancer to Gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156711_bib91","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2026.156711_bib92","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.prp.2026.156711_bib93","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","article-title":"Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)","volume":"24","author":"Dearden","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib94","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib95","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib96","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or Chemotherapy for Non\u2013Small-Cell Lung Cancer with Mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156711_bib97","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib98","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or Carboplatin\u2013Paclitaxel in Pulmonary Adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156711_bib99","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR -Mutated Advanced Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156711_bib100","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156711_bib101","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2217\/fon-2021-0923","article-title":"MARIPOSA: phase 3 study of first-line amivantamab+ lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer","volume":"18","author":"Cho","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib102","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib103","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jtho.2019.12.126","article-title":"Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases","volume":"15","author":"Yang","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib104","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156711_bib105","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-10-2692","article-title":"Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation","volume":"17","author":"Oxnard","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156711_bib106","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum\u2013Pemetrexed in EGFR T790M\u2013Positive Lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156711_bib107","doi-asserted-by":"crossref","first-page":"S1669","DOI":"10.1016\/j.annonc.2023.10.593","article-title":"514MO Acquired mechanisms of resistance to first-line (1L) osimertinib with or without platinum-based chemotherapy (CT) in EGFR-mutated (EGFRm) advanced NSCLC: Preliminary data from FLAURA2","volume":"34","author":"Lee","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib108","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2025.04.003","article-title":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and\/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study","volume":"36","author":"de Marinis","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib109","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(24)00270-5","article-title":"Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial","volume":"25","author":"Wu","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib110","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor\u2013Mutated Non\u2013Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib111","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.canlet.2016.11.008","article-title":"EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance","volume":"385","author":"Wang","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2026.156711_bib112","doi-asserted-by":"crossref","first-page":"9662","DOI":"10.1021\/acs.jmedchem.2c00704","article-title":"Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer","volume":"65","author":"Eno","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.prp.2026.156711_bib113","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS Proteins and Their Regulators in Human Disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.prp.2026.156711_bib114","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1097\/JTO.0000000000000305","article-title":"KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma","volume":"9","author":"Nadal","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib115","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156711_bib116","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS3161","article-title":"A phase I\/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation","volume":"37","author":"Papadopoulos","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib117","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cancergen.2016.03.001","article-title":"The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma","volume":"209","author":"Biernacka","year":"2016","journal-title":"Cancer Genet."},{"key":"10.1016\/j.prp.2026.156711_bib118","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-021-01121-2","article-title":"Targeted therapy in advanced non-small cell lung cancer: current advances and future trends","volume":"14","author":"Majeed","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib119","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9003","article-title":"Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer","volume":"39","author":"Skoulidis","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib120","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS\u2013MAPK Reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prp.2026.156711_bib121","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in Non\u2013Small-Cell Lung Cancer Harboring a KRAS G12C Mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156711_bib122","doi-asserted-by":"crossref","first-page":"589","DOI":"10.21037\/jtd.2018.01.129","article-title":"BRAF inhibitors in metastatic non-small cell lung cancer","volume":"10","author":"Anguera","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.prp.2026.156711_bib123","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156711_bib124","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jtho.2025.05.023","article-title":"Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC\u2014A Brief Report","volume":"20","author":"Riely","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib125","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.2586","article-title":"A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations","volume":"36","author":"Janku","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib126","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e21204","article-title":"Class II and class III BRAF mutations in patients with advanced non-small cell lung cancer (NSCLC): Clinical characteristics, mutation patterns, and survival outcomes","volume":"41","author":"Rasokat","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib127","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical Features and Outcome of Patients With Non\u2013Small-Cell Lung Cancer Who Harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib128","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1200\/JCO.20.00505","article-title":"Brigatinib Versus Crizotinib in Advanced ALK Inhibitor\u2013Naive ALK-Positive Non\u2013Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial","volume":"38","author":"Camidge","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib129","article-title":"SAF-189s in previously treated patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC): Results from the dose-finding portion in a single-arm, first-in-human","author":"Yang","year":"2020","journal-title":"phase I\/II Study"},{"key":"10.1016\/j.prp.2026.156711_bib130","doi-asserted-by":"crossref","unstructured":"Y. Fang, H. Pan, S. Lu, H. Hu, Q. Lu, A phase I study to evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TQ-B3101., (2020).","DOI":"10.1200\/JCO.2020.38.15_suppl.e21705"},{"key":"10.1016\/j.prp.2026.156711_bib131","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1038\/s41467-025-59744-9","article-title":"Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial","volume":"16","author":"Arrieta","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2026.156711_bib132","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/cac2.12524","article-title":"Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study","volume":"44","author":"Zheng","year":"2024","journal-title":"Cancer Commun."},{"key":"10.1016\/j.prp.2026.156711_bib133","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1080\/14656566.2020.1774552","article-title":"Pharmacological and clinical properties of lorlatinib in the treatment of ALK -rearranged advanced non-small cell lung cancer","volume":"21","author":"El Darsa","year":"2020","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.prp.2026.156711_bib134","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non\u2013Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study","volume":"42","author":"Solomon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib135","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ejmech.2017.04.032","article-title":"First macrocyclic 3 rd -generation ALK inhibitor for treatment of ALK\/ROS1 cancer: Clinical and designing strategy update of lorlatinib","volume":"134","author":"Basit","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.prp.2026.156711_bib136","doi-asserted-by":"crossref","first-page":"S383","DOI":"10.21037\/tlcr.2019.05.10","article-title":"Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?","volume":"8","author":"Mogenet","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.prp.2026.156711_bib137","first-page":"20","article-title":"ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies","author":"Poei","year":"2024","journal-title":"Cancer Drug. Resist. 7"},{"key":"10.1016\/j.prp.2026.156711_bib138","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s43018-022-00399-6","article-title":"Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer","volume":"3","author":"Shiba-Ishii","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.prp.2026.156711_bib139","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2147\/CMAR.S283199","article-title":"Update on lorlatinib: role in reducing the risk of disease progression in ALK-positive NSCLC","author":"Yun","year":"2022","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.prp.2026.156711_bib140","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib141","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib142","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1097\/JTO.0b013e31826baf83","article-title":"Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non\u2013Small-Cell Lung Cancer","volume":"7","author":"Chin","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib143","article-title":"Efficacy of Taletrectinib (AB-106\/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies","volume":"2","author":"Ou","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.prp.2026.156711_bib144","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.8018","article-title":"Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC","volume":"33","author":"Shaw","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108743","article-title":"Prognostic impact and characteristics of ROS1 fusion in patients with surgically resected lung adenocarcinoma","volume":"208","author":"Yu","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.prp.2026.156711_bib146","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) Is a Next-Generation ROS1\/TRK\/ALK Inhibitor That Potently Inhibits ROS1\/TRK\/ALK Solvent- Front Mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prp.2026.156711_bib147","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1634\/theoncologist.2013-0095","article-title":"Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions","volume":"18","author":"Gainor","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.prp.2026.156711_bib148","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.2513","article-title":"A phase 1 study of the next-generation ALK\/ROS1\/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK\/ROS1\/NTRK+ cancers (TRIDENT-1)","volume":"36","author":"Drilon","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib149","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1158\/1078-0432.CCR-19-2777","article-title":"Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Na\u00efve and Solvent-Front\u2013Mutant ROS1-Rearranged Non\u2013Small Cell Lung Cancer","volume":"26","author":"Yun","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156711_bib150","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS9637","article-title":"TRIDENT-1: A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid tumors harboring ROS1 or NTRK1-3 rearrangements","volume":"38","author":"Doebele","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib151","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/14737140.2019.1643239","article-title":"Capmatinib for the treatment of non-small cell lung cancer","volume":"19","author":"Vansteenkiste","year":"2019","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.prp.2026.156711_bib152","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ddr.22033","article-title":"Cyclic carbamates in medicine: A clinical perspective","volume":"84","author":"Prasher","year":"2023","journal-title":"Drug. Dev. Res."},{"key":"10.1016\/j.prp.2026.156711_bib153","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9084","article-title":"Intracranial activity of tepotinib in patients (pts) with MET exon 14 ( MET ex14) skipping NSCLC enrolled in VISION","volume":"39","author":"Patel","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib154","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.9509","article-title":"Capmatinib in patients with high-level MET -amplified advanced non\u2013small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study","volume":"38","author":"Wolf","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib155","article-title":"Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study","volume":"39","author":"Wolf","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib156","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-022-01299-z","article-title":"Foretinib can overcome common on-target resistance mutations after capmatinib\/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation","volume":"15","author":"Fujino","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib157","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1158\/1078-0432.CCR-19-3608","article-title":"Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14\u2013mutant NSCLC","volume":"26","author":"Recondo","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156711_bib158","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.ijrobp.2021.10.185","article-title":"METex14 ctDNA dynamics & resistance mechanisms detected in liquid biopsy (LBx) from patients (pts) with METex14 skipping NSCLC treated with tepotinib, In","volume":"112","author":"Paik","year":"2022","journal-title":"t. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.prp.2026.156711_bib159","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9065","article-title":"Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC)","volume":"39","author":"Besse","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib160","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of Selpercatinib in RET Fusion\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156711_bib161","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO-25-01489","article-title":"Final Efficacy and Safety Data From the Phase I\/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion\u2013Positive Non\u2013Small Cell Lung Cancer","volume":"44","author":"Besse","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib162","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9065","article-title":"Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC)","volume":"39","author":"Besse","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib163","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS3162","article-title":"A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer","volume":"37","author":"Schoffski","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib165","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12916-022-02245-z","article-title":"Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial","volume":"20","author":"Song","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.prp.2026.156711_bib166","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2012.45.6095","article-title":"Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives","volume":"31","author":"Mazi\u00e8res","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib167","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.lungcan.2018.10.019","article-title":"Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study","volume":"126","author":"Koga","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.prp.2026.156711_bib168","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156711_bib169","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1097\/01.JTO.0000473485.38553.f0","article-title":"Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer","volume":"10","author":"Farago","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib170","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion\u2013Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156711_bib171","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1470-2045(19)30789-2","article-title":"Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours","volume":"21","author":"Lassen","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib172","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.3081","article-title":"First-time in-human study of VMD-928, an oral allosteric TrkA selective inhibitor targeting TrkA protein overexpression, in patients with solid tumors or lymphoma","volume":"39","author":"Chung","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib173","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1200\/JCO.2011.38.0899","article-title":"Cancer Immunotherapy Comes of Age","volume":"29","author":"Topalian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib174","doi-asserted-by":"crossref","first-page":"686","DOI":"10.18632\/oncotarget.28230","article-title":"Response to immunotherapy in KRAS G12C mutated NSCLC: a single-centre retrospective observational study","volume":"13","author":"Sciortino","year":"2022","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2026.156711_bib175","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9016","article-title":"STK11\/LKB1 co-mutations to predict for de novo resistance to PD-1\/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma","volume":"35","author":"Skoulidis","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107510","article-title":"Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11\/KEAP1 comutations across PD-L1 levels","volume":"190","author":"Sun","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.prp.2026.156711_bib177","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/annonc\/mdy334","article-title":"PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers","volume":"29","author":"Sabari","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib178","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s10555-025-10245-7","article-title":"Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy","volume":"44","author":"Ramos-Ram\u00edrez","year":"2025","journal-title":"Cancer Metastas-.-. Rev."},{"key":"10.1016\/j.prp.2026.156711_bib179","article-title":"Targetable driver gene\u2013tumor immune microenvironment axis in non-small cell lung cancer: from molecular pathological mechanisms to precision immunotherapy stratification strategies","volume":"17","author":"Chen","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156711_bib180","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1146\/annurev-cancerbio-030419-033502","article-title":"Acquired Resistance in Lung Cancer","volume":"4","author":"Tulpule","year":"2020","journal-title":"Annu. Rev. Cancer Biol."},{"key":"10.1016\/j.prp.2026.156711_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107522","article-title":"Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights","volume":"210","author":"Meador","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.prp.2026.156711_bib182","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1215530","article-title":"Acquired Resistance to Crizotinib from a Mutation in CD74 \u2013 ROS1","volume":"368","author":"Awad","year":"2013","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156711_bib183","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.lungcan.2020.05.018","article-title":"BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer","volume":"146","author":"Shi","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.prp.2026.156711_bib184","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41698-017-0007-0","article-title":"Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma","volume":"1","author":"Neel","year":"2017","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib185","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3892\/ijo.2021.5270","article-title":"Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review)","volume":"59","author":"He","year":"2021","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib186","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1164\/rccm.202410-1959PP","article-title":"Non\u2013Small Cell Lung Cancer to Small Cell Lung Cancer Transformation: A Clinical Challenge","volume":"211","author":"Papavassiliou","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.prp.2026.156711_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103966","article-title":"Tumor plasticity and therapeutic resistance in oncogene-addicted non-small cell lung cancer: from preclinical observations to clinical implications","volume":"184","author":"Toyokawa","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.prp.2026.156711_bib188","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3390\/cancers14081931","article-title":"Acquired Mechanisms of Resistance to Osimertinib\u2014The Next Challenge","volume":"14","author":"R\u00edos-Hoyo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prp.2026.156711_bib189","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib190","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2026.156711_bib191","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/annonc\/mdy474","article-title":"Correction to: \u201cMetastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Planchard","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib192","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 Insertion\u2013Mutated Non\u2013Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib193","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1200\/JCO.23.00774","article-title":"Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF V600 -Mutant Metastatic Non\u2013Small-Cell Lung Cancer","volume":"41","author":"Riely","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib194","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor\u2013Resistant, EGFR -Mutated Non\u2013Small Cell Lung Cancer","volume":"12","author":"J\u00e4nne","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prp.2026.156711_bib195","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib196","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer: current status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.prp.2026.156711_bib197","doi-asserted-by":"crossref","unstructured":"J. Wu, Z. Liu, T. Huang, Y. Wang, M.M. Song, T. Song, G. Long, X. Zhang, X. Li, L. Zhang, Cerebrospinal fluid circulating tumor <scp>DNA<\/scp> depicts profiling of brain metastasis in <scp>NSCLC<\/scp>, Mol. Oncol. 17 (2023) 810\u2013824. https:\/\/doi.org\/10.1002\/1878-0261.13357.","DOI":"10.1002\/1878-0261.13357"},{"key":"10.1016\/j.prp.2026.156711_bib198","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1158\/1078-0432.CCR-22-1749","article-title":"A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non\u2013Small Cell Lung Cancer (LC-SCRUM-Liquid)","volume":"29","author":"Sugimoto","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156711_bib199","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/1759-7714.13300","article-title":"Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples","volume":"11","author":"Ma","year":"2020","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.prp.2026.156711_bib200","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1158\/1078-0432.CCR-18-0969","article-title":"Clonal Hematopoiesis: A New Layer in the Liquid Biopsy Story in Lung Cancer","volume":"24","author":"Bauml","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156711_bib201","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/1878-0261.12646","article-title":"The potential of combined mutation sequencing of plasma circulating cell-free DNA and matched white blood cells for treatment response prediction","volume":"14","author":"van der Leest","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib202","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1158\/1078-0432.CCR-18-0143","article-title":"False-Positive Plasma Genotyping Due to Clonal Hematopoiesis","volume":"24","author":"Hu","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156711_bib203","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4103\/ijc.IJC_215_17","article-title":"Repeat biopsy in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer: Feasibility, limitations, and clinical utility in Indian patients","volume":"54","author":"Zanwar","year":"2017","journal-title":"Indian. J. Cancer"},{"key":"10.1016\/j.prp.2026.156711_bib204","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2022.02.006","article-title":"Histologic transformation of epidermal growth factor receptor\u2013mutated lung cancer","volume":"166","author":"Fujimoto","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.prp.2026.156711_bib205","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00986-2018","article-title":"Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning","volume":"53","author":"Wang","year":"2019","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.prp.2026.156711_bib206","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101494","article-title":"Predicting oncogene mutations of lung cancer using deep learning and histopathologic features on whole-slide images","volume":"24","author":"Tomita","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib207","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002118","article-title":"Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET\/CT images","volume":"9","author":"Mu","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2026.156711_bib208","article-title":"Dissecting transcriptome signals of anti-PD-1 response in lung adenocarcinoma","volume":"14","author":"Lee","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2026.156711_bib209","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1576461","article-title":"Machine learning approaches for EGFR mutation status prediction in NSCLC: an updated systematic review","volume":"15","author":"Haixian","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2026.156711_bib210","article-title":"Deep learning-based analysis of EGFR mutation prevalence in lung adenocarcinoma <scp>H&E","volume":"10","author":"Park","year":"2024","journal-title":"<\/scp> whole slide Images J. Pathol. Clin. Res."},{"key":"10.1016\/j.prp.2026.156711_bib211","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41568-025-00824-9","article-title":"Acquired resistance in cancer: towards targeted therapeutic strategies","volume":"25","author":"Soragni","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2026.156711_bib212","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1200\/EDBK_280845","article-title":"Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology","volume":"40","author":"Gumusay","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"10.1016\/j.prp.2026.156711_bib213","first-page":"27","article-title":"Acquired resistance to molecularly targeted therapies for cancer","author":"Stubbs","year":"2025","journal-title":"Cancer Drug. Resist. 8"},{"key":"10.1016\/j.prp.2026.156711_bib214","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1252652","article-title":"A narrative review of antibody\u2013drug conjugates in EGFR-mutated non-small cell lung cancer","volume":"13","author":"Hsu","year":"2023","journal-title":"Front. Oncol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S034403382600364X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S034403382600364X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:41:38Z","timestamp":1793475698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S034403382600364X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":214,"alternative-id":["S034403382600364X"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156711","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarker-guided targeted therapy in lung adenocarcinoma: A concise review of precision oncology advances, resistance mechanisms, and emerging strategies","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156711","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156711"}}